ABSTRACT
The efficacy of allergen immunotherapy (AIT) is well supported by evidence from trials and meta-analyses. However, its actual performance in daily practice may be diminished by several pitfalls, including inappropriate patient selection, and, especially, the use of allergen extracts of insufficient quality. We performed a survey, the Allergen Immunotherapy Decision Analysis, to evaluate which criteria specialists use to choose products for sublingual immunotherapy (SLIT) in adult patients suffering from allergic respiratory disease. We surveyed a total of 169 Italian allergists randomly chosen from a database belonging to a market research company (Lexis Ricerche, Milan, Italy). The survey was performed between October and November 2012 under the aegis of the European Center for Allergy Research Foundation and consisted of a questionnaire-based electronic survey prepared by a scientific board of 12 AIT experts. The questionnaire comprised two parts, the first of which contained 14 items to be ranked by each participant according to the importance assigned to each when choosing SLIT products. The physicians' rankings assigned major importance to the level of evidence-based validation of efficacy and safety, standardization of the product, efficacy based on personal experience, and defined content(s) of the major allergen(s) in micrograms. The results of this survey show that Italian allergists rank the quality-related characteristics of allergen extracts as highly important when choosing products for AIT. The allergists' preference for high-quality products should be addressed by regulatory agencies and by producers.
Subject(s)
Allergens/immunology , Hypersensitivity/immunology , Hypersensitivity/therapy , Physicians/statistics & numerical data , Specialization/statistics & numerical data , Sublingual Immunotherapy/statistics & numerical data , Adult , Aged , Female , Health Care Surveys , Humans , Italy , Male , Middle Aged , Sublingual Immunotherapy/adverse effects , Sublingual Immunotherapy/standards , Young AdultABSTRACT
The aims of this observational "proof-of-concept" study were to analyze the clinical/psychological characteristics and gut microbiota/mycobiota composition of individuals with suspected non-celiac gluten/wheat sensitivity (NCGS/WS) according to responses to the double-blind-placebo-controlled (DBPC) crossover gluten challenge test. Fifty individuals with suspected NCGS/WS were subjected to the DBPC challenge test; anthropometric measurements, psychometric questionnaires, and fecal samples were collected. Twenty-seven (54%) participants were gluten responsive (NCGS), and 23 were placebo responsive, with an order effect. NCGS individuals displayed a significantly lower risk of eating disorders and a higher mental health score when compared to placebo-responsive participants, confirmed by multiple logistic regression analyses (OR = 0.87; 95% CI 0.76-0.98, p = 0.021, and OR = 1.30; 95% CI 1.06-1.59, p = 0.009, respectively). Principal coordinate analyses based on microbiota composition showed a separation by the DBPC response (p = 0.039). For Bacteroides (p = 0.05) and Parabacteroides (p = 0.007), the frequency of amplicon sequence variants was lower, and that for Blautia (p = 0.009) and Streptococcus (p = 0.004) was higher in NCGS individuals at multiple regression analyses. No difference in the mycobiota composition was detected between the groups. In conclusion, almost half of the individuals with suspected gluten sensitivity reported symptoms with placebo; they showed lower mental health scores, increased risk for eating disorders, and a different gut microbiota composition.
Subject(s)
Feeding and Eating Disorders/epidemiology , Gastrointestinal Microbiome/immunology , Glutens/administration & dosage , Mycobiome/immunology , Wheat Hypersensitivity/diagnosis , Adult , Cross-Over Studies , Double-Blind Method , Feces/microbiology , Feeding and Eating Disorders/diagnosis , Feeding and Eating Disorders/immunology , Feeding and Eating Disorders/psychology , Female , Glutens/immunology , Humans , Immunologic Tests/methods , Male , Mental Health , Middle Aged , Placebos/administration & dosage , Proof of Concept Study , Psychometrics , Risk Assessment , Risk Factors , Self Report , Wheat Hypersensitivity/immunology , Wheat Hypersensitivity/psychologySubject(s)
Anaphylaxis/chemically induced , Anti-Bacterial Agents/adverse effects , Bacitracin/administration & dosage , Drug Hypersensitivity/etiology , Neomycin/adverse effects , Administration, Cutaneous , Anaphylaxis/therapy , Anti-Bacterial Agents/administration & dosage , Combined Modality Therapy , Drug Combinations , Drug Hypersensitivity/therapy , Humans , Male , Middle Aged , Neomycin/administration & dosage , Patch Tests , Toes/injuries , Wound Infection/drug therapySubject(s)
Allergens/immunology , Asthma/drug therapy , Conjunctivitis, Allergic/drug therapy , Dermatitis, Atopic/drug therapy , Dermatophagoides pteronyssinus/immunology , Rhinitis, Allergic/drug therapy , Sublingual Immunotherapy , Vaccines/therapeutic use , Adolescent , Animals , Asthma/complications , Asthma/diagnosis , Asthma/immunology , Child , Child, Preschool , Conjunctivitis, Allergic/complications , Conjunctivitis, Allergic/diagnosis , Conjunctivitis, Allergic/immunology , Dermatitis, Atopic/complications , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/immunology , Drug Administration Schedule , Female , Humans , Male , Rhinitis, Allergic/complications , Rhinitis, Allergic/diagnosis , Rhinitis, Allergic/immunology , Skin/drug effects , Skin/immunology , Skin/pathology , Vaccines/administration & dosageABSTRACT
There are wide differences in estimated incidence and prevalence of anaphylaxis because of the absence, until recently, of a universal consensus on the definition of anaphylaxis and the different source of collected data. We aimed to estimate the incidence of food anaphylaxis based on the database of Piemonte Region (Italy) Reference Center for Severe Allergic Reactions. All cases of severe food allergic reactions reported in 2010 were studied. Clinical data associated to the reports were evaluated according to National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network diagnostic criteria of anaphylaxis. 75 % of the 778 cases were classified as food anaphylaxis (incidence of 13/100,000 person-years, ranging from 9.9 in adults to 29/100,000 person-years in children). Nuts were the most frequent foods causing anaphylaxis. Milk and eggs were responsible for anaphylaxis more often in children, while peach, vegetables and crustaceans were in adults. Cardiovascular symptoms were more frequent in adults. Gastrointestinal involvement was more frequent in children. A high prevalence of respiratory allergic comorbidities was observed. Food is an important cause of anaphylaxis, particularly in subjects with respiratory allergic comorbidities. Children and adults differ in triggers and clinical presentation of anaphylaxis.
Subject(s)
Anaphylaxis/epidemiology , Food Hypersensitivity/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Humans , Incidence , Infant , Italy/epidemiology , Male , Middle Aged , Prevalence , Registries , Risk FactorsABSTRACT
OBJECTIVES: This analysis is focused on the comparison of costs of allergic rhinitis (R) alone or with allergic asthma (R + A) in grass pollen allergy, for subjects treated with sublingual immunotherapy (SLIT) and symptomatic drugs, versus standard care controls. METHODS: The SIMAP (Sublingual IMmunotherapy in Allergic Patients) study is a longitudinal observational database operated by a network of Allergy centers. Patients suffering from grass pollen allergy were included in this analysis and assigned to SLIT (plus drugs as needed) or to treatment with drugs alone. Outcome measures included use of medications, SLIT, visits and tests. Costs were assessed from the perspective of the Italian National Health Service; unit costs were obtained from published sources to produce an average cost/patient for the first year after enrolment. RESULTS: One hundred and two patients were analyzed. Demographics were comparable in the two groups. Overall per patient yearly cost of treatment was higher in SLIT patients, both in the whole sample (euro311 vs. euro180/patient), in the R (euro288 vs. euro116) and R + A (euro362 vs. euro230) subpopulations, with R + A patients generating more costs than R patients in both groups. Nevertheless considerable savings were obtained in the cost of symptomatic drugs (-22% for R; -34% for R + A) in SLIT patients. CONCLUSIONS: Other studies have shown that SLIT can reduce the use of drugs for asthma and rhinitis, but this is the first time this outcome has been demonstrated in a routine care population (in the medical practice environment of an observational study) within the first year of treatment.
Subject(s)
Anti-Allergic Agents/economics , Anti-Allergic Agents/therapeutic use , Desensitization, Immunologic/economics , Rhinitis, Allergic, Seasonal/economics , Rhinitis, Allergic, Seasonal/therapy , Administration, Sublingual , Adolescent , Adult , Asthma/complications , Asthma/economics , Asthma/therapy , Case-Control Studies , Costs and Cost Analysis , Databases, Factual , Desensitization, Immunologic/methods , Female , Follow-Up Studies , Humans , Male , Middle Aged , Poaceae/immunology , Rhinitis, Allergic, Seasonal/complicationsABSTRACT
BACKGROUND: Specific subcutaneous immunotherapy (SCIT) with house dust mite (HDM) preparation has recently been shown to improve eczema in patients with atopic dermatitis (AD). So far, there is less data regarding efficacy and safety of specific sublingual immunotherapy (SLIT) in patients with AD. STUDY AIM: To evaluate in an open non-controlled, non-randomized pilot trial the effect of SLIT with HDM allergen extracts preparation (SLITone, ALK Abellò Italy) on SCORAD in adult patients with mild-moderate AD. PATIENTS AND METHODS: 86 Subjects (53 females and 33 males) between 3 and 60 years of age with AD and IgE-proved (Class > 2) HDM sensitization were enrolled after their informed consent in the trial. Exclusion criteria were severe asthma and treatment with systemic or high potent topical corticosteroids or immunosuppressant agents. Patients were treated with SLIT (Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts: SLITone, ALK-Abellò) for at least 12 months. SCORAD was evaluated at baseline and after 12 months of treatment. RESULTS: Baseline SCORAD value, mean +/- SD, was 43.3 +/- 13.7 (range 15-84). After 1 year of SLIT, mean +/- SD, SCORAD value was reduced to 23.7 +/- 13.3 (range: 0-65) (p = 0.0001; unpaired t-test vs. baseline). This was a 46% reduction in SCORAD in comparison with baseline value. A significant improvement, defined as a SCORAD reduction of > 30%, was observed in 51 out of 86 patients (59%). In 5 patients (5.8%) SCORAD values did not change at the end of the observation period. In 30 patients (35%) the SCORAD reduction after SIT was Subject(s)
Dermatitis, Atopic/therapy
, Immunotherapy
, Mites
, Administration, Sublingual
, Adolescent
, Adrenal Cortex Hormones/administration & dosage
, Adult
, Animals
, Child
, Child, Preschool
, Female
, Histamine H1 Antagonists/administration & dosage
, Humans
, Male
, Middle Aged
, Pilot Projects
, Prospective Studies
ABSTRACT
Compliance is a major determinant for allergy treatment, especially in children. Sublingual immunotherapy (SLIT) is self-managed at home, and no quantitative data on pediatric adherence are available. We studied the compliance in a large real-life setting. A simplified schedule of SLIT was used, consisting of a 10-day updosing phase followed by maintenance treatment in monodose containers to be taken daily (SLITOne). Italian specialists throughout Italy assessed the compliance in children who were newly prescribed SLIT according to guidelines. Parents were contacted with unscheduled telephone interviews at the third and sixth month of therapy and asked to count at that moment the remaining vials. Data from 71 children (38 boys, age range 2-13 yr) were enclosed in the database. Thirty had rhinoconjunctivitis, four asthma and 37 rhinoconjunctivitis + asthma. SLIT was prescribed for: mites in 57 (81%) subjects, grasses in 11 (15%) and 3 (4%) grass + olive mixture. Compliance data were available for all children at 3 months, and for 56 at 6 months. At 3 months, 85% of subjects had a compliance rate >75% (69% of them adhered >90%). At 6 months, 84% had a compliance rate >75% (66% of them adhered >90%). In four cases SLIT was discontinued for economical reasons, and in one case (1.4%) for side effects probably related to therapy. These data obtained in a quite large sample of children and in real-life confirm that the compliance with SLITOne is good, despite the therapy managed at home.